For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival

Oncology Times Broadcast News

For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival

Charles Coombes at ECCO15-ESMO34 on the Intergroup Exemestane Study showing a big increase in survival for patients with early breast cancer randomized to have their adjuvant therapy switched to exemestane after 2-3 years of tamoxifen, compared with those who remained on tamoxifen for the entire 5 years of endocrine therapy.